We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)

News   Sep 27, 2012

 
CTN Accepted for SymBio’s Japan Phase 1 Trial of Rigosertib (SyB L-1101)
 
 
Advertisement
 

RELATED ARTICLES

Ultrapotent Compound Could Help Combat C. difficile

News

Scientists from Purdue University have advanced novel compounds that they have designed to help treat patients with Clostridioides difficile.

READ MORE

Team Uncovers New Mechanism of Action Against SARS-CoV-2 by Remdesivir

News

Researchers have discovered a novel, second mechanism of action by the antiviral drug remdesivir against SARS-CoV-2, according to findings published in the Journal of Biological Chemistry.

READ MORE

Study Investigates Racial Disparities in Clinical Trial Recruitment

News

Scientists are increasingly turning to electronic-based recruitment methods to encourage participation in clinical trials. Little is known about how this use of technology compares to more traditional clinical trial recruitment strategies, and some researchers worry that an overreliance on technology has the potential to exclude an eligible and interested diverse participant population.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE